BETA
Your AI-Trained Oncology Knowledge Connection!
Tanios S. Bekaii-Saab, MD, joins Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for early- and intermediate-stage hepatocellular carcinoma.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer
Fruquintinib plus chemotherapy and a PD-1 inhibitor elicited an ORR of 80.0% with all partial responses in patients with treatment-naïve gastric/GEJ cancer.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer
Disitamab vedotin, toripalimab, and trastuzumab demonstrated superior response rates and efficacy in HER2-overexpressing metastatic gastric cancers.
Educating Patients and Clinicians on End-of-Life Care and Discussions
Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.
Elraglusib Plus Chemo Enhances Survival Vs Chemo Alone in Metastatic PDAC
A survival benefit was noted when elraglusib was added to chemotherapy for patients with metastatic PDAC.
Adjuvant Nivolumab Provides Sustained Benefit in Resected Esophageal/GEJ Cancer
Five-year follow-up confirms adjuvant nivolumab's sustained disease-free and distant metastasis-free survival benefits in resected esophageal/GEJ cancer post-CRT.